Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECIPE Trial
jRCT2041180037Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Adjusted INCAT Disability Scale. Started Mar 2019; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2041180037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041180037.